PolyPeptide Group AG, a specialized global contract development and manufacturing organization (CDMO) for peptide-based active pharmaceutical ingredients, announced that its shareholders approved all proposals put forward by the board of directors at an extraordinary general meeting held on October 26, 2026. The approvals included the election of five new board members and the removal of transfer restrictions and voting limitations from the company's articles of association, according to a release distributed via NEWMEDIAWIRE.
The newly elected board members are John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang, and Joonkyung Seong, each serving a term ending at the conclusion of the next annual general meeting. John Chongbo Rim was elected as chair of the board, while Cheol Woo Ryu and Seungho Ryu were elected as members of the Remuneration and Nomination Committee, also for terms ending at the next annual general meeting. These elections are subject to and effective as of the settlement of the public tender offer by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd., for all publicly held registered shares of PolyPeptide.
In addition, shareholders resolved to remove the transfer restrictions (Vinkulierung) and voting limitations (Stimmrechtsbeschränkungen) from PolyPeptide's articles of association, subject to the satisfaction or waiver of all offer conditions set forth in the offer prospectus of Samsung Peptide AG dated August 31, 2026, except for the condition in section B.7.1(e) of that prospectus.
The approvals are significant because they clear the way for the takeover by Samsung Biologics, a move that could reshape the competitive landscape for peptide-based active pharmaceutical ingredients. PolyPeptide, which dates back to 1952, operates a global network of six GMP-certified facilities across Europe, the U.S., and India. It serves a fast-growing market with products and services spanning pre-pre-clinical to commercial stages, and its portfolio includes significant exposure to metabolic diseases, including GLP-1 therapies. For readers and industry observers, the integration of PolyPeptide into Samsung Biologics could affect supply chains and capacity for peptide manufacturing, a sector that has gained prominence due to the rising demand for GLP-1 drugs.
The board changes and the removal of transfer restrictions are contingent on the tender offer settlement, meaning the new governance structure will only take effect once the offer conditions are met or waived. This conditionality underscores the transaction's complexity and the need for regulatory and shareholder alignment. The full details of the EGM results are available in the PolyPeptide_EGM Results 2026_ENG document, and the original release can be viewed on www.newmediawire.com. PolyPeptide's shares are listed on the SIX Swiss Exchange under the ticker PPGN.
